

**CLAIMS**

1. Use of fosinopril or a pharmaceutically acceptable salt thereof to prepare a medicament for reducing the risk of occurrence of a cardiovascular event in a dialysis patient.

2. Use according to Claim 1, in which the cardiovascular event is a cardiac insufficiency.

3. Use according to Claim 2, in which the cardiovascular event is a cardiac insufficiency decompensation.

4. Use according to Claim 1, in which the cardiovascular event is a myocardial infarction.

5. Use according to Claim 1, in which the cardiovascular event is an angina.

6. Use according to Claim 1, in which the cardiovascular event is a stroke.

7. Use according to Claim 1, in which the cardiovascular event is a non-fatal cardiac arrest.

8. Use according to Claim 1, in which the cardiovascular event is a death of cardiovascular origin.

9. Use according to one of Claims 1 to 8, in which the patient is a blood dialysis patient.

10. Use according to one of Claims 1 to 8, in which the dialysis patient presents left-ventricular hypertrophy.

11. Use according to one of Claims 1 to 10, in which the patient undergoes a dialysis treatment on account of a chronic kidney disease in the terminal phase.

12. Use according to one of Claims 1 to 11, in which the patient has been undergoing a dialysis treatment for at least six months.

13. Use according to one of Claims 1 to 12, in which the patient undergoes a dialysis session at least three times a week.

14. Use according to one of Claims 1 to 13, in which the patient is a man or a woman 50 to 80 years old.

15. Use according to one of Claims 1 to 14, in which the fosinopril is in the form of fosinopril sodium.

16. Use according to one of Claims 1 to 15, in which the medicament is intended for oral administration.

5        17. Use according to Claim 16, in which the medicament comprises from 5 to 20 mg of fosinopril or a pharmaceutically acceptable salt thereof.

18. Use according to Claim 16 or 17, in which the medicament is intended for a daily administration of about 0.01 mg/kg to about 25 mg/kg of fosinopril or a pharmaceutically acceptable salt thereof.

10        19. Use according to Claim 18, in which the medicament is intended for a daily administration of about 10 mg of fosinopril or a pharmaceutically acceptable salt thereof.